0.4 ML adalimumab-fkjp 50 MG/ML Prefilled Syringe [Hulio] — RxCUI 2640415
RxNorm drug concept · Semantic branded drug
RxCUI 2640415
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2640415
Official name0.4 ML adalimumab-fkjp 50 MG/ML Prefilled Syringe [Hulio]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as0.4 ML Hulio 50 MG/ML Prefilled Syringe; Hulio 20 MG in 0.4 ML Prefilled Syringe; Hulio 20 MG per 0.4 ML Prefilled Syringe
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Adalimumab Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Adalimumab is approved for quite a few inflammatory conditions — rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psor...
- What conditions is adalimumab actually approved to treat?
- You'll use either an autoinjector pen or a prefilled syringe, depending on what your doctor prescribes. Before injecting, take it out of the refrigerator and let it sit for 15 to 3...
- How do I give myself this injection at home?
🕸️ Concept Web — How 0.4 ML adalimumab-fkjp 50 MG/ML Prefilled Syring... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
0.4 ML adalimumab-fkjp 50 MG/ML Prefilled Syringe [Hulio]
RxCUI 2640415 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Adalimumab
327361IN -
Adalimumab-fkjp
2640402PIN
-
Adalimumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Hulio
2640406BN
-
Hulio
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Adalimumab Prefilled Syringe
727702SCDF -
Adalimumab-fkjp Prefilled Syringe
2646033SCDFP -
Adalimumab Injectable Product
1163691SCDG -
Adalimumab-fkjp Injectable Product
2661140SCDGP -
Adalimumab Prefilled Syringe [Hulio]
2640414SBDF -
Adalimumab-fkjp Prefilled Syringe [Hulio]
2655533SBDFP -
Hulio Injectable Product
2640408SBDG -
Prefilled Syringe
721656DF - +1 more in this family
-
Adalimumab Prefilled Syringe
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
0.4 ML adalimumab-fkjp 50 MG/ML Prefilled Syringe
2640412SCD -
Adalimumab-fkjp 50 MG/ML
2640403SCDC -
Adalimumab-fkjp 50 MG/ML [Hulio]
2640407SBDC
-
0.4 ML adalimumab-fkjp 50 MG/ML Prefilled Syringe
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
0.4 ML adalimumab-fkjp 50 MG/ML Prefilled Syringe
SCD · 2640412 -
Adalimumab-fkjp 50 MG/ML
SCDC · 2640403 -
Adalimumab Prefilled Syringe
SCDF · 727702 -
Adalimumab-fkjp Prefilled Syringe
SCDFP · 2646033 -
Adalimumab Injectable Product
SCDG · 1163691 -
Adalimumab-fkjp Injectable Product
SCDGP · 2661140
Brand-Name Concepts
-
Adalimumab-fkjp 50 MG/ML [Hulio]
SBDC · 2640407 -
Adalimumab Prefilled Syringe [Hulio]
SBDF · 2640414 -
Adalimumab-fkjp Prefilled Syringe [Hulio]
SBDFP · 2655533 -
Hulio Injectable Product
SBDG · 2640408 -
Hulio
BN · 2640406
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 2640415 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 83257-0016-42 | 2 TRAY in 1 KIT (83257-016-42) / 1 KIT in 1 TRAY * 2 TRAY... | HULIO | Biocon Biologics Inc | 2023-12-30 |
| 83257-0019-32 | 2 TRAY in 1 KIT (83257-019-32) / 1 KIT in 1 TRAY * 2 TRAY... | HULIO | Biocon Biologics Inc | 2023-12-30 |
Observed labelers:
Biocon Biologics Inc (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.